In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mim: Taking a Generic Approach to PBM

Executive Summary

Pharmacy benefit management has historically driven drug costs lower, at least in part by cutting dispensing fees and minimizing the pharmacist's role in managed care decision-making. But Mim is turning that around, using pharmacists' unique role in the dispensing episode to push higher-than-industry-norm levels of generic substitution.

You may also be interested in...



China-US Divide Deepens On Covid Vaccines, Azar Taiwan Visit

China has shown willingness to go tit-for-tat in its bilateral disputes with the US and the latest comments from US officials show an underlying distrust over clinical data and vaccines safety in China, raising fresh concerns just when collaboration is needed to accelerate availability of the first vaccines in the global pandemic.

Coronavirus Notebook: Middle Ground Pricing As Moderna Reaches 100m Dose US Agreement

Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA vaccine. Also, Evidence Accelerator's next joint parallel analysis projects are remdesivir in hospitalized patients and coagulopathy.

QUOTED. 12 August 2020. Rep. James Clyburn.

House Democrats criticized the administration’s response to the pandemic in a new report. See what Rep. James Clyburn, chairman of the Select Subcommittee on the Coronavirus Crisis, said about it here.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

WI965023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel